

II. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended) A method for the prevention of the loss of visual acuity associated with AMD, which comprises, ~~juxtasclerally~~ administering a pharmaceutically effective amount of the compound anecortave acetate or its corresponding alcohol, wherein said administering is by a method selected from the group consisting of posterior juxtasccleral injection, juxtasccleral implant, intravitreal injection, or implant.

Claim 2 (original) The method of claim 1, wherein the compound is administered as a juxtasccleral depot.

Claim 3 (original) The method of claim 2, wherein the depot comprises 3 mg – 30 mg of compound.

Claim 4 (original) The method of claim 3, wherein the depot comprises 15 mg of compound.

Claim 5 (currently amended) A method for maintaining visual acuity in a person suffering from AMD, which comprises ~~juxtascclerally~~ administering a pharmaceutically effective amount of the compound anecortave acetate or its corresponding alcohol, wherein said administering is by a method selected from the group consisting of posterior juxtasccleral injection, juxtasccleral implant, intravitreal injection, or implant.

Claim 6 (original) The method of claim 5, wherein the compound is administered as a juxtasccleral depot.

Claim 7 (original) The method of claim 6, wherein the depot comprises 3 mg – 30 mg of compound.

Claim 8 (original) The method of claim 7, wherein the depot comprises 15 mg of compound.

Claim 9 (currently amended) A method for the inhibition of lesion growth associated with AMD, which comprises ~~juxtasclerally~~ administering a pharmaceutically effective amount of the compound anecortave acetate or its corresponding alcohol, wherein said administering is by a method selected from the group consisting of posterior juxtasceral injection, juxtasceral implant, intravitreal injection, or implant.

Claim 10 (original) The method of claim 9, wherein the compound is administered as a juxtasceral depot.

Claim 11 (original) The method of claim 10, wherein the depot comprises 3 mg – 30 mg of compound.

Claim 12 (original) The method of claim 11, wherein the depot comprises 15 mg of compound.

Claim 13 (original) The method of ~~claim~~ any one of claims 1, 5, or 9, wherein the compound is administered in a juxtasceral implant.

Claim 14 (new) A method for inhibiting blood vessel growth associated with AMD, said method comprising administering a pharmaceutically effective amount of the compound anecortave acetate or its accompanying alcohol, wherein the administering is by juxtasceral injection, intravitreal injection, juxtasceral implant, or other implant.

Claim 15 (new) The method of claim 14, wherein the amount of compound administered is from 3 mg to 30 mg.

Claim 16 (new) The method of claim 15, wherein the amount of compound administered is 15 mg.

Claim 17 (new) The method of claim 9, wherein the lesion is a predominantly classic subfoveal lesion.

Claim 18 (new) The method of claim 9, wherein the lesion is a minimally classic lesion.

III. REMARKS

A. Status of the Claims


Claims 1-13 were originally filed with the case on June 26, 2003. No Office Action has issued in the present case. Claims 1, 5, 9 and 13 are amended herein to clarify the subject matter of the invention. Claims 14-18 are added herein. Support for the amendments can be found throughout the specification and in the claims as originally filed. More specifically, support for amendments to claims 1, 5 and 9 and for new claim 14 can be found at page 10, lines 34-36. Support for new claims 14-16 can also be found at page 1, lines 28-31 and in the claims as originally filed. Support for new claims 17 and 18 can be found at page 6, lines 4-6.

B. Conclusion

Applicants respectfully request that the claims be considered as amended herein.

The Examiner is invited to contact the undersigned attorney at (817) 551-4321 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,



Teresa J. Schultz
Reg. No. 40,526
Attorney for Applicants

ALCON RESEARCH, LTD.
6201 S. Freeway, Q-148
Fort Worth, TX 76134-2099
(817) 551-4321

Date: 16 Oct. 2003